CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia
Peking University · Cell Medica (Switzerland) · +6 more institutions
Indexed incrossrefpubmed
Abstract
Disruption in lymphocytes was only approximately 5%, which indicates the need for further research into this approach. (Funded by the Beijing Municipal Science and Technology Commission and others; ClinicalTrials.gov number, NCT03164135.).
Citation impact
451
total citations
- FWCI
- 24.01
- Percentile
- 100%
- References
- 27
Citations per year
Authors
23- LXLei XuCorresponding
Peking University, Cell Medica (Switzerland), State Key Laboratory of Natural and Biomimetic Drugs
- JWJun Wang
Peking University, Cell Medica (Switzerland), State Key Laboratory of Natural and Biomimetic Drugs
- YLYulin Liu
Center for Life Sciences, Cell Medica (Switzerland)
- LXLiangfu Xie
Center for Life Sciences, Cell Medica (Switzerland)
- BSBin Su
Capital Medical University, Beijing YouAn Hospital, Cell Medica (Switzerland)
Topics & keywords
Topics
Keywords
- CRISPR
- Genome editing
- Context (archaeology)
- Leukemia
- Genetic enhancement
- Transplantation
- Progenitor cell
- Hematopoietic stem cell transplantation
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.